A citation-based method for searching scientific literature

Annikka Weissferdt, Apar Pataer, Ara A Vaporciyan, Arlene M Correa, Boris Sepesi, Cesar A Moran, Ignacio I Wistuba, Jack A Roth, Jitesh Baban Shewale, John V Heymach, Neda Kalhor, Tina Cascone, Wayne L Hofstetter, J Jack Lee, Stephen G Swisher. Clin Lung Cancer 2020
Times Cited: 47







List of co-cited articles
295 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
65

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Matthew D Hellmann, Jamie E Chaft, William N William, Valerie Rusch, Katherine M W Pisters, Neda Kalhor, Apar Pataer, William D Travis, Stephen G Swisher, Mark G Kris. Lancet Oncol 2014
277
61

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Apar Pataer, Neda Kalhor, Arlene M Correa, Maria Gabriela Raso, Jeremy J Erasmus, Edward S Kim, Carmen Behrens, J Jack Lee, Jack A Roth, David J Stewart,[...]. J Thorac Oncol 2012
205
48

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Catherine A Shu, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Claud M Grigg, Aliyah Pabani, Robert F Garofano, Mark B Stoopler, Simon K Cheng, Abby White,[...]. Lancet Oncol 2020
246
48

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna C B Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben,[...]. Nat Med 2021
167
48

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño,[...]. Lancet Oncol 2020
260
46


IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
William D Travis, Sanja Dacic, Ignacio Wistuba, Lynette Sholl, Prasad Adusumilli, Lukas Bubendorf, Paul Bunn, Tina Cascone, Jamie Chaft, Gang Chen,[...]. J Thorac Oncol 2020
108
38

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Shugeng Gao, Ning Li, Shunyu Gao, Qi Xue, Jianming Ying, Shuhang Wang, Xiuli Tao, Jun Zhao, Yousheng Mao, Bing Wang,[...]. J Thorac Oncol 2020
166
38

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome, Alan Mitchell, Vanessa Bolejack. J Thorac Oncol 2016
29

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Jean-Pierre Pignon, Hélène Tribodet, Giorgio V Scagliotti, Jean-Yves Douillard, Frances A Shepherd, Richard J Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour,[...]. J Clin Oncol 2008
25

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Yang Qu, Katsura Emoto, Takashi Eguchi, Rania G Aly, Hua Zheng, Jamie E Chaft, Kay See Tan, David R Jones, Mark G Kris, Prasad S Adusumilli,[...]. J Thorac Oncol 2019
55
23

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
T R Cottrell, E D Thompson, P M Forde, J E Stein, A S Duffield, V Anagnostou, N Rekhtman, R A Anders, J D Cuda, P B Illei,[...]. Ann Oncol 2018
190
23

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng,[...]. J Clin Oncol 2019
124
21

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Sacha I Rothschild, Alfred Zippelius, Eric I Eboulet, Spasenija Savic Prince, Daniel Betticher, Adrienne Bettini, Martin Früh, Markus Joerger, Didier Lardinois, Hans Gelpke,[...]. J Clin Oncol 2021
86
21

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
21

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
Jamie E Chaft, Valerie Rusch, Michelle S Ginsberg, Paul K Paik, David J Finley, Mark G Kris, Katharine A R Price, Christopher G Azzoli, Matthew G Fury, Gregory J Riely,[...]. J Thorac Oncol 2013
86
19

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Matthew J Bott, Stephen C Yang, Bernard J Park, Prasad S Adusumilli, Valerie W Rusch, James M Isbell, Robert J Downey, Julie R Brahmer, Richard Battafarano, Errol Bush,[...]. J Thorac Cardiovasc Surg 2019
141
19

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
19

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Enriqueta Felip, Rafael Rosell, José Antonio Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, José Luis González-Larriba, Antonio Torres,[...]. J Clin Oncol 2010
232
19

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Gideon M Blumenthal, Paul A Bunn, Jamie E Chaft, Caroline E McCoach, Edith A Perez, Giorgio V Scagliotti, David P Carbone, Hugo J W L Aerts, Dara L Aisner, Jonas Bergh,[...]. J Thorac Oncol 2018
94
19

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
Tina Cascone, Kathryn A Gold, Stephen G Swisher, Diane D Liu, Frank V Fossella, Boris Sepesi, Apar Pataer, Annikka Weissferdt, Neda Kalhor, Ara A Vaporciyan,[...]. Ann Thorac Surg 2018
22
36

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
555
17

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, Michael A Davies, Merrick I Ross, Isabella C Glitza, Janice N Cormier, Carol Lewis, Wen-Jen Hwu, Ehab Hanna,[...]. Nat Med 2018
417
17

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Annikka Weissferdt, Apar Pataer, Stephen G Swisher, John V Heymach, Don L Gibbons, Tina Cascone, Boris Sepesi. Lung Cancer 2021
10
80

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Kathy S Albain, R Suzanne Swann, Valerie W Rusch, Andrew T Turrisi, Frances A Shepherd, Colum Smith, Yuhchyau Chen, Robert B Livingston, Richard H Feins, David R Gandara,[...]. Lancet 2009
966
14

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Tina Cascone, Boris Sepesi, Heather Y Lin, Neda Kalhor, Edwin R Parra, Mei Jiang, Myrna C B Godoy, Jianjun Zhang, Frank V Fossella, Anne S Tsao,[...]. Clin Cancer Res 2020
15
46

Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William N William, Apar Pataer, Neda Kalhor, Arlene M Correa, David C Rice, Ignacio I Wistuba, John Heymach, J Jack Lee, Edward S Kim, Reginald Munden,[...]. J Thorac Oncol 2013
77
14

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.
Julie E Stein, Evan J Lipson, Tricia R Cottrell, Patrick M Forde, Robert A Anders, Ashley Cimino-Mathews, Elizabeth D Thompson, Mohamad E Allaf, Mark Yarchoan, Josephine Feliciano,[...]. Clin Cancer Res 2020
55
14

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
14

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Nasser K Altorki, Timothy E McGraw, Alain C Borczuk, Ashish Saxena, Jeffrey L Port, Brendon M Stiles, Benjamin E Lee, Nicholas J Sanfilippo, Ronald J Scheff, Bradley B Pua,[...]. Lancet Oncol 2021
92
14

Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Apar Pataer, Annikka Weissferdt, Ara A Vaporciyan, Arlene M Correa, Boris Sepesi, Ignacio I Wistuba, John V Heymach, Tina Cascone, Stephen G Swisher. J Thorac Oncol 2021
11
63

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.
K Junker, M Thomas, K Schulmann, F Klinke, U Bosse, K M Müller. J Cancer Res Clin Oncol 1997
126
12

Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.
K Junker, K Langner, F Klinke, U Bosse, M Thomas. Chest 2001
113
12

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Miklos Pless, Roger Stupp, Hans-Beat Ris, Rolf A Stahel, Walter Weder, Sandra Thierstein, Marie-Aline Gerard, Alexandros Xyrafas, Martin Früh, Richard Cathomas,[...]. Lancet 2015
209
12

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi,[...]. Oncologist 2019
48
12

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
12

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Jing Liu, Stephen J Blake, Michelle C R Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S O'Donnell, Stacey Allen, Mark J Smyth,[...]. Cancer Discov 2016
411
12

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
Aadel A Chaudhuri, Jacob J Chabon, Alexander F Lovejoy, Aaron M Newman, Henning Stehr, Tej D Azad, Michael S Khodadoust, Mohammad Shahrokh Esfahani, Chih Long Liu, Li Zhou,[...]. Cancer Discov 2017
458
12

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Joshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, Kellie N Smith, Franco Verde, Marianna Zahurak, Mara Lanis, Joseph C Murray, Hok Yee Chan, Caroline McCarthy,[...]. J Immunother Cancer 2020
63
12

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
12

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.
Monika Pradhan, Mathieu Chocry, Don L Gibbons, Boris Sepesi, Tina Cascone. Transl Lung Cancer Res 2021
20
30

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, Alexander C Huang, Michael T Tetzlaff, Bart A van de Wiel, Serigne Lo, Ahmad A Tarhini, Elizabeth M Burton, Thomas E Pennington,[...]. Nat Med 2021
122
12

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu,[...]. Lancet 2021
219
12

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad, Enriqueta Felip, Stephen R Broderick, Julie R Brahmer, Scott J Swanson,[...]. N Engl J Med 2022
174
12

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
R Rosell, J Gómez-Codina, C Camps, J Maestre, J Padille, A Cantó, J L Mate, S Li, J Roig, A Olazábal. N Engl J Med 1994
991
10

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
J A Roth, F Fossella, R Komaki, M B Ryan, J B Putnam, J S Lee, H Dhingra, L De Caro, M Chasen, M McGavran. J Natl Cancer Inst 1994
868
10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
10

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu,[...]. Lancet Oncol 2018
324
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.